This clinical study investigates the immunological effects of tuberculin purified protein derivative (TPPD) therapy in patients with anogenital warts (AGW) caused by human papillomavirus (HPV). Twelve AGW patients received intralesional TPPD injections (5 tuberculin units) once weekly for six weeks and were compared with twelve control patients. Tissue samples were collected at baseline and after two injections for immunohistochemical analysis of interferon-alpha (IFN-α) and interleukin-2 (IL-2) expression. Blood samples were collected at baseline and after six injections to measure serum levels of IFN-α and IL-2 using ELISA. The study aims to evaluate TPPD as a potential immunotherapeutic agent by assessing cytokine responses associated with AGW regression.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in Tissue IFN-α Expression in AGW Lesions (Measured by IHC)
Timeframe: Baseline and Week 2
Change in Tissue IL-2 Expression in AGW Lesions (Measured by IHC)
Timeframe: Baseline and Week 2
Percentage Reduction in AGW Lesion Volume
Timeframe: Baseline to Week 6
Change in Serum IFN-α Levels (Measured by ELISA)
Timeframe: Baseline and Week 6
Change in Serum IL-2 Levels (Measured by ELISA)
Timeframe: Baseline and Week 6